Tag: breast cancer test

Labs in British Columbia Meet Tough PT Standards

CEO SUMMARY: Facing a crisis due to several highly publicized deficiencies in lab testing, pathologists in Canada are using proficiency testing (PT) to improve standards. In British Columbia, PT is mandatory and every lab is evaluated every quarter. Pathologists in BC recommend that every province and territory adopt mandatory proficiency testing. Currently only British Columbia

View Article

Canadian Pathologists Start PT Testing for ER/PR

CEO SUMMARY: Experts point out that widely publicized episodes of lab testing deficiencies in several provinces are signs that chronic underfunding of lab testing services is a key factor in these failures. To restore public confidence in breast cancer testing, the Canadian Association of Pathologists is developing a voluntary proficiency testing system for hospital labs

View Article

July 7, 2008 “Intelligence: Late Breaking Lab News”

GI Pathology, PLLC, of Memphis, Tennessee, announced that it has contracted to be a national gastrointestinal (GI) pathology laboratory provider with CIGNA HealthCare of Hartford, Connecticut. It also has a five year, national provider contract with UnitedHeathCare.
SPENDING CUTS ADVERSELY AFFECT CANADIAN LABS
Widely-publicized errors in pathology services have caught the attention of the Canadian public. Pathologist

View Article

December 18, 2006 “Intelligence: Late Breaking Lab News”

Last Friday, Luminex Corporation of Austin, Texas announced that it would acquire Tm Bioscience Corp. of Toronto, Ontario. Luminex will pay $44 million, which represents a 41.5% premium for Tm shares based on the December 14 closing price. Tm Bioscience has tests for DNA-based diagnostics, including tests for infectious diseases and genetic mutations related to

View Article

Genomic Health, TriPath Imaging, Bio-Reference Labs, Canadian Patient Registry

PREDICTIVE TESTING FOR RECURRENT BREAST CANCER
LABORATORY TESTS DESIGNED to predict the recurrence of breast cancer are picking up momentum. First to market was Genomic Health Inc.’s Oncotype DX™ breast cancer test. Now TriPath Imaging, Inc. is reporting favorable results from studies of its ProEx Br markers for breast cancer.

Since introducing Oncotype DX in 2004, Genomic

View Article